Market Overview

Egalet Tells Benzinga 'We Don't Have Any Idea Of Timing' Related To FDA Decision On ARYMO ER; BZ Note: Notable Analyst Tells Benzinga Typical Delay-To-Approval On Opiods Runs 2-4 Weeks


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for EGLT

Mar 2018Cantor FitzgeraldMaintainsOverweightOverweight
Jan 2018Stifel NicolausDowngradesBuyHold
Nov 2017Gabelli & Co.DowngradesBuyHold

View More Analyst Ratings for EGLT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News FDA Exclusives Analyst Ratings General


Related Articles (EGLT)